NovaBridge Biosciences (NBP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
NovaBridge Biosciences stock (NBP) is currently trading at $2.52. NovaBridge Biosciences PS ratio (Price-to-Sales) is 25.39. Analyst consensus price target for NBP is $8.25. WallStSmart rates NBP as Sell.
- NBP PE ratio analysis and historical PE chart
- NBP PS ratio (Price-to-Sales) history and trend
- NBP intrinsic value — DCF, Graham Number, EPV models
- NBP stock price prediction 2025 2026 2027 2028 2029 2030
- NBP fair value vs current price
- NBP insider transactions and insider buying
- Is NBP undervalued or overvalued?
- NovaBridge Biosciences financial analysis — revenue, earnings, cash flow
- NBP Piotroski F-Score and Altman Z-Score
- NBP analyst price target and Smart Rating
NovaBridge Biosciences
📊 No data available
Try selecting a different time range
Smart Analysis
NovaBridge Biosciences (NBP) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and price/sales. Significant fundamental concerns warrant caution or avoidance.
NovaBridge Biosciences (NBP) Key Strengths (1)
Trading at 1.15x book value, attractively priced
Supporting Valuation Data
NovaBridge Biosciences (NBP) Areas to Watch (3)
Very expensive at 25.4x annual revenue
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 43.12%
Supporting Valuation Data
NovaBridge Biosciences (NBP) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.15) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Market Cap, Institutional Own.. Some valuation metrics including Price/Sales (25.39) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NBP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NBP's Price-to-Sales ratio of 25.39x sits near its historical average of 25.39x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 25.39x set in Mar 2026, and 0% above its historical low of 25.39x in Mar 2026.
Insider Transactions
Loading insider activity...
About NovaBridge Biosciences(NBP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
China
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is headquartered in Rockville, Maryland.